These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

269 related articles for article (PubMed ID: 10822464)

  • 1. Interferon treatment of renal cell carcinoma. Current status and future prospects.
    Krown SE
    Cancer; 1987 Feb; 59(3 Suppl):647-51. PubMed ID: 10822464
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Phase II trial of interferon-beta-serine in metastatic renal cell carcinoma.
    Kinney P; Triozzi P; Young D; Drago J; Behrens B; Wise H; Rinehart JJ
    J Clin Oncol; 1990 May; 8(5):881-5. PubMed ID: 2332772
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Interferon alfa-2a versus combination therapy with interferon alfa-2a, interleukin-2, and fluorouracil in patients with untreated metastatic renal cell carcinoma (MRC RE04/EORTC GU 30012): an open-label randomised trial.
    Gore ME; Griffin CL; Hancock B; Patel PM; Pyle L; Aitchison M; James N; Oliver RT; Mardiak J; Hussain T; Sylvester R; Parmar MK; Royston P; Mulders PF
    Lancet; 2010 Feb; 375(9715):641-8. PubMed ID: 20153039
    [TBL] [Abstract][Full Text] [Related]  

  • 4. A prospective randomized trial of alpha 2B-interferon/gamma-interferon or the combination in advanced metastatic renal cell carcinoma.
    Foon K; Doroshow J; Bonnem E; Fefer A; Graham S; Grosh B; Narayan P; Elias L; Harvey H; Schulof R
    J Biol Response Mod; 1988 Dec; 7(6):540-5. PubMed ID: 3145964
    [TBL] [Abstract][Full Text] [Related]  

  • 5. [Impact of immunochemotherapy on survival of patients with metastatic renal cell carcinoma. A retrospective study comparing interferon-alpha-2a/vinblastine versus interferon-alpha-2a/interleukin-2/5-fluorouracil].
    May M; Helke C; Bock M; Hoschke B
    Urologe A; 2004 Sep; 43(9):1111-9. PubMed ID: 15232686
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Pilot study of interleukin-2 and lymphokine-activated killer cells combined with immunomodulatory doses of chemotherapy and sequenced with interferon alfa-2a in patients with metastatic melanoma and renal cell carcinoma.
    Sznol M; Clark JW; Smith JW; Steis RG; Urba WJ; Rubinstein LV; VanderMolen LA; Janik J; Sharfman WH; Fenton RG
    J Natl Cancer Inst; 1992 Jun; 84(12):929-37. PubMed ID: 1629914
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Recombinant interferon alfa-2a with or without vinblastine in metastatic renal cell carcinoma: results of a European multi-center phase III study.
    Fosså SD; Martinelli G; Otto U; Schneider G; Wander H; Oberling F; Bauer HW; Achtnicht U; Holdener EE
    Ann Oncol; 1992 Apr; 3(4):301-5. PubMed ID: 1390305
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Effect of alpha-interferon alone and combined with other antineoplastic agents on renal cell carcinoma determined by the tetrazolium microculture assay.
    Homma Y; Aso Y
    Eur Urol; 1994; 25(2):164-70. PubMed ID: 8137859
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Interferon therapy for metastatic renal cell carcinoma.
    Swanson DA; Quesada JR
    Semin Surg Oncol; 1988; 4(3):174-7. PubMed ID: 3142007
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Subcutaneous administration of interleukin-2 and interferon-alpha 2b in advanced renal cell carcinoma: long-term results.
    Locatelli MC; Facendola G; Pizzocaro G; Piva L; Pegoraro C; Pallavicini EB; Signaroldi A; Meregalli M; Lombardi F; Beretta GD; Scanzi F; Labianca R; Dallavalle G; Luporini G
    Cancer Detect Prev; 1999; 23(2):172-6. PubMed ID: 10101599
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Interferon alfa-2a in advanced renal cell carcinoma: treatment results and survival in 159 patients with long-term follow-up.
    Minasian LM; Motzer RJ; Gluck L; Mazumdar M; Vlamis V; Krown SE
    J Clin Oncol; 1993 Jul; 11(7):1368-75. PubMed ID: 8315435
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Daily alternating administration of high-dose alpha-2b-interferon and interleukin-2 bolus infusion in metastatic renal cell cancer. A phase II study.
    Bergmann L; Fenchel K; Weidmann E; Enzinger HM; Jahn B; Jonas D; Mitrou PS
    Cancer; 1993 Sep; 72(5):1733-42. PubMed ID: 8348502
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Stratification by risk factors predicts survival on the active treatment arm in a randomized phase II study of interferon-gamma plus/minus interferon-alpha in advanced renal cell carcinoma (E6890).
    Dutcher JP; Fine JP; Krigel RL; Murphy BA; Schaefer PL; Ernstoff MS; Loehrer PJ
    Med Oncol; 2003; 20(3):271-81. PubMed ID: 14514977
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Clinical and immunologic effects of subcutaneously administered interleukin-12 and interferon alfa-2b: phase I trial of patients with metastatic renal cell carcinoma or malignant melanoma.
    Alatrash G; Hutson TE; Molto L; Richmond A; Nemec C; Mekhail T; Elson P; Tannenbaum C; Olencki T; Finke J; Bukowski RM
    J Clin Oncol; 2004 Jul; 22(14):2891-900. PubMed ID: 15254058
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Interleukin-2- and interferon alfa-2a-based immunochemotherapy in advanced renal cell carcinoma: a Prospectively Randomized Trial of the German Cooperative Renal Carcinoma Chemoimmunotherapy Group (DGCIN).
    Atzpodien J; Kirchner H; Jonas U; Bergmann L; Schott H; Heynemann H; Fornara P; Loening SA; Roigas J; Müller SC; Bodenstein H; Pomer S; Metzner B; Rebmann U; Oberneder R; Siebels M; Wandert T; Puchberger T; Reitz M;
    J Clin Oncol; 2004 Apr; 22(7):1188-94. PubMed ID: 14981107
    [TBL] [Abstract][Full Text] [Related]  

  • 16. A phase-II study of combination of pegylated interferon alfa-2a and capecitabine in locally advanced or metastatic renal cell cancer.
    Sunela KL; Koskinen S; Kellokumpu-Lehtinen PL
    Cancer Chemother Pharmacol; 2010 May; 66(1):59-67. PubMed ID: 19771431
    [TBL] [Abstract][Full Text] [Related]  

  • 17. A phase II trial of interleukin-2 and interferon alfa-2a in patients with advanced renal cell carcinoma.
    Ilson DH; Motzer RJ; Kradin RL; Vogelzang NJ; Bajorin DF; Scher HI; Nanus D; O'Moore P; Marathias K; Bosl GJ
    J Clin Oncol; 1992 Jul; 10(7):1124-30. PubMed ID: 1607918
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Concomitant administration of recombinant human interleukin-2 and recombinant interferon alfa-2A: an active outpatient regimen in metastatic renal cell carcinoma.
    Figlin RA; Belldegrun A; Moldawer N; Zeffren J; deKernion J
    J Clin Oncol; 1992 Mar; 10(3):414-21. PubMed ID: 1482425
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Combination therapy with capecitabine and interferon alfa-2A in patients with advanced renal cell carcinoma: a phase II study.
    Padrik P; Leppik K; Arak A
    Urol Oncol; 2004; 22(5):387-92. PubMed ID: 15464918
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Cytokine combinations: therapeutic use in patients with advanced renal cell carcinoma.
    Bukowski RM
    Semin Oncol; 2000 Apr; 27(2):204-12. PubMed ID: 10768599
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 14.